OncoLens, which is a Health Tech startup and is working on cancer treatment, has raised around $16 Million from Cross Border Impact Ventures and BIP Capital, and also includes existing investors, SeedToB Capital and Martin Ventures.
OncoLens is one of the fastest-growing companies in the Inc 5000’s 2024 and has a research network and cancer treatment platform will use this amount to take its research to the next level using AI-enabled clinical and workflow solutions that it provides to its customers, which include prominent names like NCIs(National Cancer Institutes), etc.
With its global clientele and partnerships, OncoLens has partnered with clinical development teams and has launched OncoLens Research Network in the EMEA (Europe, the Middle East, and Africa) area to further its trial and to get genuine results.
Anju Mathew is the CEO and Co-Founder at OncoLens, and she herself has experienced the wrath of cancer in her family which motivated her to get the best available treatment of cancer using the latest technological advancements such as Artificial Intelligence. So, she started OncoLens which provides planning, accreditation, tumor board management, and quality improvement to patients. Previously, she has served as head at McKesson’s Medical Surgical business unit and has led many successful breakthroughs and partnerships.
OncoLens has around 225+ cancer centers and life science partners that help the company to create a meaningful impact on the lives.
Swastik Saraf is the Founder and Managing Editor of TheMedSector. With a background in data journalism and healthcare research, he specializes in aggregating public health metrics, analyzing institutional data, and mapping out regional healthcare infrastructure. Swastik leads the data compilation team at TheMedSector, ensuring all directory tracking is built on verified primary sources before undergoing formal clinical review.
